← Back to Clinical Trials
Recruiting NCT06574087

NCT06574087 Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06574087
Status Recruiting
Phase
Sponsor PCK Marine Hospital in Gdynia
Condition HPV-Related Carcinoma
Study Type INTERVENTIONAL
Enrollment 248 participants
Start Date 2023-01-13
Primary Completion 2027-01

Eligibility & Interventions

Sex Female only
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
hrHPV test and cytology

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 248 participants in total. It began in 2023-01-13 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary aim of the study is to determine the total risk of AIN in group of HPV-RGD survivors and additionally to establish an exact risk for each of HPV-related gynecological precancers/cancers. Moreover, the most appropriate screening test for HSIL(AIN) in this group of patients will be determined. It will be effectuated by performing two kinds of tests: hrHPV test for the 14 most common oncogenic HPV types and the liquid cytology from both the lower genital tract and anal canal with subsequent high resolution anoscopy (HRA) with potential biopsy/excision of suspected lesions and histopathological examination.

Eligibility Criteria

Inclusion Criteria: * HPV related gynecological disease confirmed in histo-pathological examination * the posibility to obtain material from gynecological organ and from anal canal

Frequently Asked Questions

Who can join the NCT06574087 clinical trial?

This trial is open to female participants only, studying HPV-Related Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06574087 currently recruiting?

Yes, NCT06574087 is actively recruiting participants. Visit ClinicalTrials.gov or contact PCK Marine Hospital in Gdynia to inquire about joining.

Where is the NCT06574087 trial being conducted?

This trial is being conducted at Gdynia, Poland.

Who is sponsoring the NCT06574087 clinical trial?

NCT06574087 is sponsored by PCK Marine Hospital in Gdynia. The trial plans to enroll 248 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology